WO2023159794A1 - 2,4-二氨基嘧啶氧化物的制备方法 - Google Patents

2,4-二氨基嘧啶氧化物的制备方法 Download PDF

Info

Publication number
WO2023159794A1
WO2023159794A1 PCT/CN2022/096786 CN2022096786W WO2023159794A1 WO 2023159794 A1 WO2023159794 A1 WO 2023159794A1 CN 2022096786 W CN2022096786 W CN 2022096786W WO 2023159794 A1 WO2023159794 A1 WO 2023159794A1
Authority
WO
WIPO (PCT)
Prior art keywords
oxopropionitrile
guanidine
reaction
hydroxypropionitrile
oxidation
Prior art date
Application number
PCT/CN2022/096786
Other languages
English (en)
French (fr)
Inventor
谈畅
李腾
张浩千
简依敏
滕欣
Original Assignee
上海蓝晶生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海蓝晶生物科技有限公司 filed Critical 上海蓝晶生物科技有限公司
Priority to JP2023557685A priority Critical patent/JP2024511069A/ja
Priority to EP22928065.6A priority patent/EP4317138A1/en
Priority to US18/284,455 priority patent/US20240076273A1/en
Publication of WO2023159794A1 publication Critical patent/WO2023159794A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • C12P17/12—Nitrogen as only ring hetero atom containing a six-membered hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/002—Nitriles (-CN)

Definitions

  • the invention relates to the technical field of synthesis of heterocyclic compounds, in particular to a preparation method of 2,4-diaminopyrimidine oxide.
  • 2,4-diaminopyrimidine oxide commercially known as Aminexil
  • Aminexil is an exclusive patented anti-hair loss ingredient developed by L'Oreal Group, which is widely used in its hair care products.
  • Many hair loss cases are often accompanied by "perifollicular fibrosis", that is, the collagen fibers around the hair follicle become thicker and harder, which hinders the insertion of the hair bulb into the deep layer of the dermis, causing the hair follicle to be squeezed and unable to deliver nutrients, resulting in hair loss.
  • the silk becomes more and more fragile and soft.
  • 2,4-Diaminopyrimidine is a relatively safe hair-fixing ingredient, which can effectively soften the cutin around the hair follicles and prolong the life of the hair follicles; it has no side effects, and persistent use can achieve the purpose of long-term hair loss prevention.
  • the object of the present invention is to provide a kind of preparation method of 2,4-diaminopyrimidine oxide.
  • the invention provides a kind of preparation method of 2,4-diaminopyrimidine oxide, described method comprises the following steps:
  • the present invention designs a brand-new synthesis route of Armenides molecules, and generates Armenes molecules from 3-oxopropionitrile and guanidine (such as guanidine hydrochloride) under oxidation conditions.
  • 3-oxopropionitrile is obtained from 3-hydroxypropionitrile, a cheap and easy-to-obtain pharmaceutical chemical, as a raw material and oxidized.
  • the synthetic route is:
  • the oxidation process can be carried out by using chemical oxidants or biological oxidases as oxidants, that is, oxidation can be carried out in the presence of chemical oxidants or biological oxidases, there is no special limitation, and suitable conditions can be selected according to different oxidants.
  • 3-Oxopropionitrile (3-Oxo-propionitrile, also known as propionitrile aldehyde) is obtained.
  • step (1) includes: oxidizing 3-hydroxypropionitrile in the presence of a chemical oxidant to obtain 3-oxopropionitrile.
  • the chemical oxidant can be a chemical reagent known in the art for oxidizing alcohols into aldehydes, including but not limited to hydrogen peroxide, KMnO 4 , KClO 3 , concentrated H 2 SO 4 , HNO 3 , MnO 2 , FeCl 3 , etc., preferably hydrogen peroxide.
  • the molar ratio of chemical oxidant to 3-hydroxypropionitrile may be 5:1-15:1 (eg 5:1, 6:1, 8:1, 10:1, 12:1, 15:1);
  • Oxidation in the presence of a chemical oxidizing agent can be performed in a heated environment.
  • the heating temperature can be 40-60°C (eg 40, 50, 60°C), and the reaction time can be 2-6h (eg 2, 3, 4, 5, 6h).
  • step (1) includes: oxidizing 3-hydroxypropionitrile in the presence of a biological oxidase to obtain 3-oxopropionitrile.
  • Biological oxidative enzymes may be broad-spectrum short-chain alcohol (generally referred to as C1-C6 alcohol) dehydrogenases and oxidases known in the art with tolerance to aldehydes, such as alcohol dehydrogenase and alcohol oxidase.
  • C1-C6 alcohol broad-spectrum short-chain alcohol
  • oxidases known in the art with tolerance to aldehydes, such as alcohol dehydrogenase and alcohol oxidase.
  • Oxidation in the presence of biological oxidative enzymes can be performed in solution.
  • the pH of the solution can be controlled at 7-8, preferably about 7.5. This can be achieved, for example, by using a phosphate buffer at a pH of about 7.5.
  • the above step (1) includes the step of purifying the obtained 3-oxopropionitrile. Purifying 3-oxopropionitrile for the next reaction can improve the purity of the final product.
  • Purification may include the following steps: 3-oxopropionitrile is dissolved in n-butanol, centrifuged, the supernatant is dried over anhydrous sodium sulfate, concentrated sulfuric acid (to adjust pH) and optional anhydrous copper sulfate (to promote cyclization) are added, Seal and heat overnight, take out the centrifuged supernatant, extract with aqueous sodium bicarbonate solution, and dry the upper organic phase with anhydrous sodium sulfate.
  • this step can be disassembled into two steps, and the change of N before and after the reaction is as follows:
  • guanidine hydrochloride guanidine hydrochloride
  • guanidine nitrate guanidine nitrate
  • a base can be added to the reaction system to convert guanidine hydrochloride into guanidine and promote the ring closure reaction.
  • the base can be a reagent known in the art for base catalysis including, but not limited to, lithium carbonate, lithium hydroxide, lithium tert-butoxide, sodium carbonate, sodium bicarbonate, sodium hydroxide, sodium phosphate, sodium methoxide, sodium ethoxide , sodium isopropoxide, sodium tert-butoxide, potassium carbonate, potassium bicarbonate, potassium hydroxide, potassium phosphate, potassium methoxide, potassium ethoxide, potassium tert-butoxide, cesium carbonate, cesium hydroxide, magnesium carbonate, magnesium hydroxide, Magnesium phosphate, magnesium oxide, magnesium methoxide, magnesium ethoxide, magnesium isopropoxide, magnesium tert-butoxide, triethylamine, diisopropylamine, diisopropylethylamine, tri-n-butylamine, pyridine, 2-methyl One of pyridine, 2,6-lutidine, 4-dimethylamino
  • the cyclization reaction can be carried out in a solvent.
  • the solvent can be a solvent known in the art that can be used as a reaction medium for 3-oxopropionitrile and guanidine and does not react with 3-oxopropionitrile and guanidine, including but not limited to methanol, ethanol, isopropanol, n-butyl Alcohol, isobutanol, isoamyl alcohol, dichloromethane, chloroform, benzene, toluene, xylene, chlorobenzene, acetonitrile, tetrahydrofuran, 2-methyltetrahydrofuran, dioxane, ethylene glycol dimethyl ether, methyl Tert-butyl ether, isopropyl acetate, n-butyl acetate, phenyl methyl ether, ethanol, isopropanol, etc.
  • Oxidation conditions can spontaneously oxidize in air, and there is a small amount of oxidant remaining in the process of preparing 3-oxopropionitrile, which will also accelerate the oxidation process, and oxidation will occur while condensation.
  • the molar ratio of guanidine to 3-oxopropionitrile is 1:1-5:1 (eg 1:1, 2:1, 3:1, 4:1, 5:1), preferably 3:1.
  • 3-oxopropionitrile here refers to purified 3-oxopropionitrile.
  • the conversion of the reactants can be made the most complete. If it is less than or greater than this ratio, there will be a large amount of raw materials remaining, resulting in reduced economic efficiency.
  • the reaction temperature in step (2) is 70-85°C, preferably 77°C; the reaction time is 20-30min. After mixing the two substrates (guanidine hydrochloride and 3-oxopropionitrile), the product can be seen as soon as 20 minutes, and the reaction is almost complete at 30 minutes.
  • the control of the reaction temperature has an influence on the reaction rate. If it is lower or higher than the reaction temperature, the reaction time will be prolonged or the product content will be reduced.
  • the preparation method of diaminopyrimidine oxide comprises the following steps:
  • 3-hydroxypropionitrile in a centrifuge tube, add chemical oxidant, the molar ratio of chemical oxidant to 3-hydroxypropionitrile is 5:1-15:1, heat at 50°C for 4h, subpackage and freeze-dry for 6h, -20 °C sealed and stored for later use, to obtain 3-oxopropionitrile freeze-dried product;
  • the preparation method of diaminopyrimidine oxide comprises the following steps:
  • the reaction of the present invention is green and mild, and realizes the synthesis of Armenic molecules from simple, cheap and readily available raw materials.
  • Fig. 1 shows the chromatogram of 3-oxopropionitrile prepared in Example 1 of the present invention.
  • Figure 2 shows the mass spectrum of 3-oxopropionitrile prepared in Example 1 of the present invention.
  • Fig. 3 shows the chromatogram of the diaminopyrimidine oxide prepared in Example 3 of the present invention.
  • Figure 4 shows the mass spectrum of the diaminopyrimidine oxide prepared in Example 3 of the present invention.
  • Fig. 5 shows the chromatogram of the diaminopyrimidine oxide prepared in Example 4 of the present invention.
  • Figure 6 shows the mass spectrum of the diaminopyrimidine oxide prepared in Example 4 of the present invention.
  • the raw materials, reagents, and methods used in the examples are conventional raw materials, reagents, and methods in the art.
  • the mass spectrometer used QTRAP 4500 triple quadrupole mass spectrometer (SCIEX company).
  • Embodiment 1 3-oxopropionitrile is synthesized
  • DNPH derivative reagent 4mg DNPH (2,4-dinitrophenylhydrazine) was dissolved in 4mL solution (1mL concentrated hydrochloric acid, 0.5mL acetonitrile, 2.5mL water) and ultrasonically dissolved, and stored at -20°C for later use.
  • Chromatographic column C18 reverse column
  • Embodiment 2 3-oxo propionitrile is synthesized
  • YPD medium 10g yeast powder; 20g peptone; 20g glucose; dissolve to 1L volume, and sterilize at 115°C for 30min. 1.5% agar should be added to the solid medium.
  • YPM medium 1 L: 10 g of yeast powder, 20 g of peptone, and 50 g of maltose. Sterilize at 115°C for 30 minutes.
  • the yeast cells Resuspend the yeast cells with 2-3mL 0.25M pH7.5 phosphate buffer, the bacterial concentration is OD 600nm ⁇ 75, break the cells in an ultrasonic breaker (power 30%, break time 10min), and then centrifuge at 8000rpm/min for 10min , discard the bacterial fragments, divide the supernatant into 2mL centrifuge tubes, add 1.5 times the volume of acetone, refrigerate for 30min, and centrifuge at 12000rpm/min for 2min, discard the supernatant, add the equivalent of the initial cell disruption supernatant to the protein precipitation Reconstitute with 1/2 volume of 0.25M phosphate buffer, centrifuge at 12000rpm/min for 2min, discard the insoluble matter, the supernatant contains oxidase with alcohol as substrate (oxidase solution), and pack at -20°C Store in the refrigerator for later use.
  • an ultrasonic breaker power 30%, break time 10min
  • the oxidase-containing supernatant obtained in the above step 1 is used to oxidize the hydroxyl group of the substrate into aldehyde.
  • the ratio given in Table 1 it is configured into 10mL substrate solution. After the substrate solution and the above-mentioned oxidase solution are mixed in a volume ratio of 1:1, they are reacted in a shaking table at 30° C. for 4 hours, and the content of the product 3-oxopropionitrile is detected by sampling.
  • the detection method was the same as in Example 1, and 2.1 mM product 3-oxopropionitrile was generated, freeze-dried for 6 hours, and sealed and stored at -20°C for future use.
  • Substrate solution stock solution concentration Dosage Final concentration Phosphate buffer at pH 7.5 1M 5000 ⁇ L 0.5M 3-Hydroxypropionitrile 14M 140 ⁇ L 0.2M Catalase 60000U/mL 10 ⁇ L 60U/mL water - 4850 ⁇ L -
  • 3-oxopropionitrile freeze-dried product prepared in Example 1
  • dissolve the sample with 300 ⁇ L of n-butanol centrifuge, dry the supernatant three times with anhydrous sodium sulfate, add 9 ⁇ L of concentrated sulfuric acid (adjust pH), seal , heated overnight at 77°C, took out and centrifuged to leave the supernatant, extracted three times with an equal volume of 0.2M aqueous sodium bicarbonate solution, and dried the upper organic phase three times with anhydrous sodium sulfate to obtain purified 3-oxopropionitrile.
  • Sample detection The sample was diluted 50 times with water and directly tested by LC-MS.
  • Chromatographic column C18 reverse column
  • Test results As shown in Figure 3 and Figure 4, most of the products are oxides, and a small part is not oxidized.
  • Sample detection The sample was diluted 50 times with water and directly tested by LC-MS.
  • Test results As shown in Figure 5 and Figure 6, most of the products are oxides, and a small part is not oxidized.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

本发明提供了一种2,4-二氨基嘧啶氧化物的制备方法。所述制备方法包括以下步骤：由3-氧代丙腈和胍在氧化条件下进行环合反应生成2,4-二氨基嘧啶氧化物。其中，3-氧代丙腈由廉价易得的医药化学品3-羟基丙腈为原料，经氧化后得到。本发明的反应绿色温和，实现从简单、价廉、易得的原料出发合成亚美尼斯分子。

Description

2,4-二氨基嘧啶氧化物的制备方法 技术领域
本发明涉及杂环化合物的合成技术领域，尤其是涉及一种2,4-二氨基嘧啶氧化物的制备方法。
背景技术
2,4-二氨基嘧啶氧化物，商业名称为亚美尼斯分子(Aminexil)，是欧莱雅集团研发的独家专利防脱成分，广泛用于其洗护发产品中。许多脱发案例往往伴随有“毛囊周纤维化”的情况，即毛囊周边的胶原纤维变厚、变硬，使得毛球向真皮的深层插入受阻，致使毛囊受到挤压，无法输送营养物质，导致发丝越来越脆弱、细软。2,4-二氨基嘧啶是一种相对安全的固发成分，能够有效软化毛囊周边的角质，延长毛囊寿命；而且无副作用，坚持使用可达到长效防脱的目的。
US3644364、US3382247、CN87104693等报道了嘧啶衍生物的制备方法，但均直接以二氨基卤代嘧啶作为底物，产物均为米诺地尔(Minoxidil)的衍生物，并未提出亚美尼斯分子的合成途径。
US2416617、WO2008/98058、WO2007/84786、WO2012/109423报道合成制备2,4-二氨基嘧啶(亚美尼斯分子前体)，主要采用卤代氮杂环前体经过氨取代合成，原料复杂昂贵，合成反应条件苛刻。早期文献报道采用3,3-二乙氧基丙腈与盐酸胍可以缩合合成2,4-二氨基嘧啶(Journal of the American Chemical Society,1950,72,2587-2593)。但3,3-二乙氧基丙腈的制备需要用乙腈、甲醇钠、甲酸乙酯为原料，在40-50个大气压的高压条件下与一氧化碳反应(US4525310)，该方法反应条件苛刻，危险性和设备要求高。
有鉴于此，特提出本发明。
发明内容
本发明的目的在于提供一种2,4-二氨基嘧啶氧化物的制备方法。
为了实现本发明的上述目的，特采用以下技术方案：
本发明提供了一种2,4-二氨基嘧啶氧化物的制备方法，所述方法包括以下步骤：
(1)3-羟基丙腈经氧化获得3-氧代丙腈；
(2)3-氧代丙腈和胍在氧化条件下进行环合反应，得到2,4-二氨基嘧啶氧化物。
本发明设计出一种全新的亚美尼斯分子合成路径，由3-氧代丙腈和胍(如盐酸胍)在氧化条件下生成亚美尼斯分子。其中，3-氧代丙腈由廉价易得的医药化学品3-羟基丙腈为原料，经氧化后得到。
合成路线为：
Figure PCTCN2022096786-appb-000001
步骤(1)
氧化过程可以采用化学氧化剂或生物氧化酶作为氧化剂来进行，即可以在化学氧化剂存在下进行氧化，也可以在生物氧化酶存在下进行氧化，没有特别限制，可以根据不同的氧化剂选择适合的条件制备得到3-氧代丙腈(3-Oxo-propionitrile，也可称为丙腈醛)。
在一些实施方式中，步骤(1)包括：将3-羟基丙腈在化学氧化剂存在下进行氧化获得3-氧代丙腈。
化学氧化剂可以为本领域已知的用于将醇氧化成醛的化学试剂，包括但不限于双氧水、KMnO 4、KClO 3、浓H 2SO 4、HNO 3、MnO 2、FeCl 3等，优选为双氧水。
化学氧化剂与3-羟基丙腈的摩尔比可以为5:1-15:1(例如5:1、6:1、8:1、10:1、12:1、15:1)；
在化学氧化剂存在下进行氧化的过程可以在加热环境中进行。加热温度可以为40-60℃(例如40、50、60℃)，反应时间可以为2-6h(例如2、3、4、5、6h)。
在一些实施方式中，步骤(1)包括：将3-羟基丙腈在生物氧化酶存在下进行氧化获得3-氧代丙腈。
生物氧化酶可以为本领域已知的具有醛耐受性的广谱短链醇(一般指C1-C6醇)脱氢酶和氧化酶，例如乙醇脱氢酶、乙醇氧化酶。
在生物氧化酶存在下进行氧化的过程可以在溶液中进行。溶液的pH可以控制在7-8，优选为约7.5。这可以通过，例如采用pH约7.5的磷酸盐缓冲剂而实现。
在一些实施方式中，上述步骤(1)包括将获得的3-氧代丙腈进行提纯的步骤。将3-氧代丙腈提纯进行下一步反应可以提高终产物纯度。
提纯可以包括如下步骤：3-氧代丙腈用正丁醇溶解，离心，上清用无水硫酸钠干燥，加入浓硫酸(调节pH)和任选的无水硫酸铜(促进成环)，密封，加热过夜，取出离心留上清液，用碳酸氢钠水溶液萃取，上层有机相再用无水硫酸钠干燥。
步骤(2)
本步骤中，3-氧代丙腈和胍在氧化条件下发生环合反应得到2,4-二氨基嘧啶氧化物。
为了更微观地反映反应过程，该步骤可以拆解为两个步骤，反应前后N的变化如下：
Figure PCTCN2022096786-appb-000002
胍可以采用胍的盐酸盐(盐酸胍)、胍的硝酸盐(硝酸胍)等，优选盐酸胍。
此时可以在反应体系中加入碱以将盐酸胍转化为胍，并促进环合反应。
碱可以为本领域已知的用作碱催化的试剂，包括但不限于碳酸锂、氢氧化锂、叔丁醇锂、碳酸钠、碳酸氢钠、氢氧化钠、磷酸钠、甲醇钠、乙醇钠、异丙醇钠、叔丁醇钠、碳酸钾、碳酸氢钾、氢氧化钾、磷酸钾、甲醇钾、乙醇钾、叔丁醇钾、碳酸铯、氢氧化铯、碳酸镁、氢氧化镁、磷酸镁、氧化镁、甲醇镁、乙醇镁、异丙醇镁、叔丁醇镁、三乙胺、二异丙基胺、二异丙基乙基胺、三正丁胺、吡啶、2-甲基吡啶、2,6-二甲基吡啶、4-二甲氨基吡啶、四氢吡咯、吗啉、哌啶或2,2,6,6-四甲基哌啶中的一种或其组合物，优选为碳酸钠、氢氧化钠、碳酸钾、碳酸氢钾或氢氧化钾等。
环合反应可以在溶剂中进行。
溶剂可以为本领域已知的能够作为3-氧代丙腈和胍反应介质且不与3-氧代丙腈和胍发生反应的溶剂，包括但不限于甲醇、乙醇、异丙醇、正丁醇、异丁醇、异戊醇、二氯甲烷、氯仿、苯、甲苯、二甲苯、氯苯、乙腈、四氢呋喃、2-甲基四氢呋喃、二氧六环、乙二醇二甲醚、甲基叔丁基醚、醋酸异丙酯、醋酸正丁酯、苯基甲基醚、乙醇、异丙醇等。
氧化条件可以在空气中自发氧化，以及制备3-氧代丙腈的过程中有残留的少量氧化剂，也会加速氧化的过程，在缩合的同时氧化就会发生。
在一些实施方式中，胍和3-氧代丙腈的摩尔比为1:1-5:1(例如1:1、2:1、3:1、4:1、5:1)，优选为3:1。
若步骤(1)进行了提纯，这里的3-氧代丙腈指提纯后的3-氧代丙腈。
通过控制两者的摩尔比，可以使反应物转化最完全，如果小于或大于该比例，会有大量原料剩余，导致经济性降低。
在一些实施方式中，步骤(2)中反应温度为70-85℃，优选为77℃；反应时间为20-30min。将两个底物(盐酸胍和3-氧代丙腈)混合后，最快在20分钟就可以看到产物，在30分钟时反应基本完全。
反应温度控制对反应速率有影响，如果小于或大于该反应温度，反应时间将有所延长，或产物含量降低。
在一些实施方式中，二氨基嘧啶氧化物的制备方法包括以下步骤：
取3-羟基丙腈置于离心管中，加入化学氧化剂，化学氧化剂与3-羟基丙腈的摩尔比为5:1-15:1，50℃加热4h，分装后冻干6h，-20℃密封保存备用，得到3-氧代丙腈冻干物；
取3-氧代丙腈冻干物用正丁醇溶解，离心，上清用无水硫酸钠干燥，加入浓硫酸，密封，加热过夜，取出离心留上清液，用等体积碳酸氢钠水溶液萃取，上层有机相再用无水硫酸钠干燥，得到提纯后的3-氧代丙腈；随后加入盐酸胍和乙醇钠乙醇溶液，盐酸胍和提纯后的3-氧代丙腈的摩尔比为1:1-5:1，密封，77℃加热30min。
在又一些实施方式中，二氨基嘧啶氧化物的制备方法包括以下步骤：
将含3-羟基丙腈的底物溶液与生物氧化酶混合，摇床反应，干燥，获得3-氧代丙腈；
取3-氧代丙腈冻干物用正丁醇溶解，离心，上清用无水硫酸钠干燥，加入无水硫酸铜和浓硫酸，密封，加热过夜，取出离心留上清液，无水硫酸钠干燥，得到提纯后的3-氧代丙腈；随后加入盐酸胍和乙醇钠乙醇溶液，盐酸胍和提纯后的3-氧代丙腈的摩尔比为1:1-5:1，密封，77℃加热30min。
有益效果
本发明的反应绿色温和，实现从简单、价廉、易得的原料出发合成亚美尼斯分子。
在上文中已经详细地描述了本发明，但是上述实施方式本质上仅是例示性，且并不欲限制本发明。此外，本文并不受前述现有技术或发明内容或以下实施例中所描述的任何理论的限制。
除非另有明确说明，在整个申请文件中的数值范围包括其中的任何子范围和以其中给定值的最小子单位递增的任何数值。除非另有明确说明，在整个申请文件中的数值表示对包括与给定值的微小偏差以及具有大约所提及的值以及具有所提及的精确值的实施方案的范围的近似度量或限制。除了在详细描述最后提供的工作实施例之外，本申请文件(包括所附权利要求)中的参数(例如，数量或条件)的所有数值在所有情况下都应被理解为被术语“大约”修饰，不管“大约”是否实际出现在该数值之前。“大约”表示所述的数值允许稍微不精确(在该值上有一些接近精确；大约或合理地接近该值；近似)。如果“大约”提供的不精确性在本领域中没有以这个普通含义来理解，则本文所用的“大约”至少表示可以通过测量和使用这些参数的普通方法产生的变化。例如，“大约”可以包括小于或等于10％，小于或等于5％，小于或等于4％，小于或等于3％，小于或等于2％，小于或等于1％或者小于或等于0.5％的变化。
附图说明
图1示出本发明实施例1制得的3-氧代丙腈的色谱图。
图2示出本发明实施例1制得的3-氧代丙腈的质谱图。
图3示出本发明实施例3制得的二氨基嘧啶氧化物的色谱图。
图4示出本发明实施例3制得的二氨基嘧啶氧化物的质谱图。
图5示出本发明实施例4制得的二氨基嘧啶氧化物的色谱图。
图6示出本发明实施例4制得的二氨基嘧啶氧化物的质谱图。
具体实施方式
下面结合实施例对本发明作进一步的说明，需要说明的是，提供以下实施例仅出于说明目的并不构成对本发明要求保护范围的限制。
除特殊说明外，在实施例中所采用的原料、试剂、方法等均为本领域常规的原料、试剂、方法。
色谱仪使用安捷伦1200。
质谱仪使用QTRAP 4500三重四极杆质谱(SCIEX公司)。
实施例1 3-氧代丙腈合成
取200μL 3-羟基丙腈置于50mL离心管中，加入1.6mL 30％双氧水，加入60μL三氯化铁水溶液(800mM)，50℃加热4h，分装3管后冻干6h，-20℃密封保存备用。
样品检测：
样品用300μL正丁醇溶解，离心，取2μL水稀释100倍，吸取10μL稀释液加10μL DNPH衍生试剂于60℃衍生30分钟再加20μL乙腈，进液相色谱和质谱检测。
DNPH衍生试剂配制方法：4mg DNPH(2,4-二硝基苯肼)溶于4mL溶液中(1mL浓盐酸，0.5mL乙腈，2.5mL水)超声溶解，-20℃保存备用。
色谱条件：
色谱柱：C18反向柱；
流动相：A(0.1％的甲酸水):B(乙腈)＝40:60；
流速：1mL/min；
检测波长：360nm；
保留时间：8.0min。
检测结果：色谱图如图1所示。质谱图如图2所示。证明产物中含有3-氧代丙腈。
实施例2 3-氧代丙腈合成
1、生物氧化酶制备：
取毕赤酵母(Pichia pastoris)菌株甘油管菌液在YPD固体培养基上进行划线活化，37℃培养3天。在YPD平板中挑一个单克隆，接到10mL YPD液体培养基中，30℃培养24小时左右，按2％-5％的接种量转接到250mL YPM液体培养基中，待OD＝1时，用甲醇(按培养基体积的1％)进行诱导，诱导48小时。菌生长至OD 600nm≈8-9，将菌液分装收到50mL离心管中，5000rpm离心10分钟，弃上清，菌体沉淀放-20℃备用。
培养基配置：
YPD培养基的配制(1L)：10g酵母粉；20g蛋白胨；20g葡萄糖；溶解至于1L体积，115℃灭菌30min。固体培养基中需添加1.5％的琼脂。
YPM培养基的配制(1L)：10g酵母粉，20g蛋白胨，50g麦芽糖。115℃灭菌30min。
用2-3mL 0.25M pH7.5磷酸缓冲液重悬酵母菌体，菌浓度为OD 600nm≈75，在超声破碎仪中破碎细胞(功率30％，破碎时间10min)，然后在8000rpm/min离心10min，弃菌体碎片沉淀，将上清分装到2mL离心管中，分别加入1.5倍体积的丙酮，冷藏30min，12000rpm/min离心2min，弃上清，蛋白沉淀中加入相当于初始细胞破碎清液1/2体积的0.25M的磷酸缓冲液进行复溶，12000rpm/min离心2min，弃去不溶物，上清中含有以醇为底物的氧化酶(氧化酶溶液)，分装后-20℃冰箱保存备用。
2、合成3-氧代丙腈
以3-羟基丙腈为底物，采用上述步骤1制备获得的含氧化酶的上清液，对底物羟基进行氧化成醛。
按表1中给出比例配置成10mL底物溶液，底物溶液与上述氧化酶溶液按1:1体积比混合后于30℃摇床反应4小时，取样检测产物3-氧代丙腈含量，检测方法同实施例1，生成2.1mM产物3-氧代丙腈，冻干6h，-20℃密封保存备用。
表1
底物溶液 储备液浓度 用量 终浓度
pH7.5的磷酸缓冲液 1M 5000μL 0.5M
3-羟基丙腈 14M 140μL 0.2M
过氧化氢酶 60000U/mL 10μL 60U/mL
水 - 4850μL -
实施例3 二氨基嘧啶氧化物的合成
取一管3-氧代丙腈冻干物(实施例1制备)，样品用300μL正丁醇溶解，离心，上清用无水硫酸钠干燥3次，加入9μL浓硫酸(调节pH)，密封，77℃加热过夜，取出离心留上清液，用等体积0.2M碳酸氢钠水溶液萃取3次，上层有机相再用无水硫酸钠干燥3次，得到提纯后的3-氧代丙腈，随后加入10mg盐酸胍(盐酸胍和提纯后的3-氧代丙腈的摩尔比为3:1)和50μL 20％的乙醇钠乙醇溶液，密封，77℃加热30min，检测产物。
样品检测：样品用水稀释50倍直接进LC-MS检测。
色谱条件：
色谱柱：C18反向柱；
流动相：A(0.1％的甲酸水):B(乙腈)＝98:2；
流速：1mL/min；
检测波长：254nm；
保留时间：3.7min。
检测结果：如图3和图4所示，产物大部分为氧化物，也有一小部分未氧化。
实施例4 二氨基嘧啶氧化物的合成
取一管3-氧代丙腈冻干物(实施例2制备)，样品用300μL正丁醇溶解，离心，上清用无水硫酸钠干燥3次，加入30mg无水硫酸铜(促进成环反应)和9μL浓硫酸(调节pH)，密封，77℃加热过夜，取出离心留上清液，无水硫酸钠干燥2次，加入10mg盐酸胍和80μL 20％的乙醇钠乙醇溶液，密封，77℃加热30min，检测产物。
样品检测：样品用水稀释50倍直接进LC-MS检测。
检测条件：同实施例3。
检测结果：如图5和图6所示，产物大部分为氧化物，也有一小部分未氧化。
以上各实施例仅用以举例说明本发明的技术方案，而非对其限制。尽管参照前述各实施例对本发明进行了详细的说明，本领域的普通技术人员应当理解：在没有脱离本发明权利要求所限定的精神和实质的范围内，可以对前述各实施例所记载的技术方案进行修改，或者对其中部分或者全部技术特征进行等同替换；而这些修改或者替换仍然在本发明权利要求所限定的范围内。

Claims (7)

  1. 一种2,4-二氨基嘧啶氧化物的制备方法，其特征在于，所述方法包括以下步骤：
    (1)3-羟基丙腈经氧化获得3-氧代丙腈；其中，
    所述氧化在化学氧化剂存在下在加热环境中进行，化学氧化剂为选自双氧水、KMnO 4、KClO 3、浓H 2SO 4、HNO 3、MnO 2、FeCl 3中的一种或几种；加热温度为40-60℃；或者
    所述氧化在生物氧化酶存在下进行，生物氧化酶选自具有醛耐受性的广谱C1-C6醇脱氢酶和C1-C6醇氧化酶；
    (2)3-氧代丙腈和胍在氧化条件下进行环合反应，得到2,4-二氨基嘧啶氧化物。
  2. 根据权利要求1所述的方法，其特征在于，化学氧化剂与3-羟基丙腈的摩尔比为5:1-15:1。
  3. 根据权利要求1所述的方法，其特征在于，所述氧化在化学氧化剂存在下的反应时间为2-6h。
  4. 根据权利要求1所述的方法，其特征在于，步骤(2)的胍和3-氧代丙腈的摩尔比为1:1-5:1。
  5. 根据权利要求4所述的方法，其特征在于，步骤(2)的反应温度为70-85℃，反应时间为20-30min。
  6. 根据权利要求1所述的方法，其特征在于，步骤(2)的胍为盐酸胍、硝酸胍中的至少一种。
  7. 根据权利要求1所述的方法，其特征在于，步骤(1)包括将3-氧代丙腈进行提纯的步骤。
PCT/CN2022/096786 2022-02-22 2022-06-02 2,4-二氨基嘧啶氧化物的制备方法 WO2023159794A1 (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2023557685A JP2024511069A (ja) 2022-02-22 2022-06-02 ２，４－ジアミノピリミジンオキサイドの製造方法
EP22928065.6A EP4317138A1 (en) 2022-02-22 2022-06-02 2,4-diaminopyrimidine oxide preparation method
US18/284,455 US20240076273A1 (en) 2022-02-22 2022-06-02 2,4-diaminopyrimidine oxide preparation method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210159583.7A CN114213340B (zh) 2022-02-22 2022-02-22 2,4-二氨基嘧啶氧化物的制备方法
CN202210159583.7 2022-02-22

Publications (1)

Publication Number Publication Date
WO2023159794A1 true WO2023159794A1 (zh) 2023-08-31

Family

ID=80709209

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/096786 WO2023159794A1 (zh) 2022-02-22 2022-06-02 2,4-二氨基嘧啶氧化物的制备方法

Country Status (5)

Country Link
US (1) US20240076273A1 (zh)
EP (1) EP4317138A1 (zh)
JP (1) JP2024511069A (zh)
CN (1) CN114213340B (zh)
WO (1) WO2023159794A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114213340B (zh) * 2022-02-22 2022-06-07 北京蓝晶微生物科技有限公司 2,4-二氨基嘧啶氧化物的制备方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2416617A (en) 1944-07-17 1947-02-25 American Cyanamid Co Preparation of 2,4-diaminopyrimidines
US3382247A (en) 1965-11-01 1968-05-07 Upjohn Co 6-amino-1, 2-dihydro-1-hydroxy-2-imino-4-phenoxypyrimidines
US3644364A (en) 1970-03-31 1972-02-22 Upjohn Co Compounds and process
US4525310A (en) 1982-02-26 1985-06-25 Dynamit Nobel Ag Method of preparing 3-alkoxy acrylonitriles
CN87104693A (zh) 1986-07-10 1988-01-20 格德昂·理查德化学工厂股份公司 嘧啶衍生物及其制备方法
WO2007084786A1 (en) 2006-01-20 2007-07-26 Novartis Ag Pyrimidine derivatives used as pi-3 kinase inhibitors
WO2008098058A1 (en) 2007-02-06 2008-08-14 Novartis Ag Pi 3-kinase inhibitors and methods of their use
WO2012109423A1 (en) 2011-02-11 2012-08-16 Dana-Farber Cancer Institute, Inc. Method of inhibiting hamartoma tumor cells
CN114213340A (zh) * 2022-02-22 2022-03-22 北京蓝晶微生物科技有限公司 2,4-二氨基嘧啶氧化物的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU87766A1 (fr) * 1990-07-20 1992-03-11 Oreal Utilisation de derives de pyrimidine 3-oxyde pour freiner la chute des cheveux et compositions topiques mises en oeuvre
CN113173887A (zh) * 2021-04-01 2021-07-27 河北利德检测技术有限公司 一种氨苯蝶啶中间体的合成方法
CN113402420A (zh) * 2021-06-23 2021-09-17 田雨 一种2-氨基,2-氰基乙酸甲酯/乙酯、2-氨基,2-氰基乙酸及其合成工艺

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2416617A (en) 1944-07-17 1947-02-25 American Cyanamid Co Preparation of 2,4-diaminopyrimidines
US3382247A (en) 1965-11-01 1968-05-07 Upjohn Co 6-amino-1, 2-dihydro-1-hydroxy-2-imino-4-phenoxypyrimidines
US3644364A (en) 1970-03-31 1972-02-22 Upjohn Co Compounds and process
US4525310A (en) 1982-02-26 1985-06-25 Dynamit Nobel Ag Method of preparing 3-alkoxy acrylonitriles
CN87104693A (zh) 1986-07-10 1988-01-20 格德昂·理查德化学工厂股份公司 嘧啶衍生物及其制备方法
WO2007084786A1 (en) 2006-01-20 2007-07-26 Novartis Ag Pyrimidine derivatives used as pi-3 kinase inhibitors
WO2008098058A1 (en) 2007-02-06 2008-08-14 Novartis Ag Pi 3-kinase inhibitors and methods of their use
WO2012109423A1 (en) 2011-02-11 2012-08-16 Dana-Farber Cancer Institute, Inc. Method of inhibiting hamartoma tumor cells
CN114213340A (zh) * 2022-02-22 2022-03-22 北京蓝晶微生物科技有限公司 2,4-二氨基嘧啶氧化物的制备方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
COWDEN WB, WARING P: "Can 15N N.M.R. be used to determine the site of N-oxidation of Pyrimidine-2,4-diamine?", AUSTRALIAN JOURNAL OF CHEMISTRY, C S I R O PUBLISHING, AU, vol. 34, no. 7, 1 January 1981 (1981-01-01), AU , pages 1539, XP093087197, ISSN: 0004-9425, DOI: 10.1071/CH9811539 *
J P FERRIS, O S ZAMEK, A M ALTBUCH, H FREIMAN: "Chemical Evolution. XVIII. Synthesis of pyrimidines from guanidine and cyanoacetaldehyde.", JOURNAL OF MOLECULAR EVOLUTION., SPRINGER VERLAG, NEW YORK, NY., US, vol. 3, no. 4, 31 December 1974 (1974-12-31), US , pages 301 - 309, XP009548302, ISSN: 0022-2844, DOI: 10.1007/BF01796045 *
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 72, 1950, pages 2587 - 2593
LIDIA S. SHUL'PINA ; DARIO VEGHINI ; ALEKSANDR R. KUDINOV ; GEORGIY B. SHUL'PIN: "Oxidation of alcohols with hydrogen peroxide catalyzed by soluble iron and osmium derivatives", REACTION KINETICS AND CATALYSIS LETTERS, SPRINGER SCIENCE+BUSINESS MEDIA, DORDRECHT, NL, vol. 88, no. 1, 1 June 2006 (2006-06-01), DORDRECHT, NL , pages 157 - 163, XP019437462, ISSN: 1588-2837, DOI: 10.1007/s11144-006-0123-2 *
ROBERTSON MICHAEL P., LEVY MATTHEW, MILLER STANLEY L.: "Prebiotic synthesis of diaminopyrimidine and thiocytosine", JOURNAL OF MOLECULAR EVOLUTION., SPRINGER VERLAG, NEW YORK, NY., US, vol. 43, no. 6, 1 December 1996 (1996-12-01), US , pages 543 - 550, XP009548303, ISSN: 0022-2844, DOI: 10.1007/BF02202102 *

Also Published As

Publication number Publication date
CN114213340B (zh) 2022-06-07
US20240076273A1 (en) 2024-03-07
EP4317138A1 (en) 2024-02-07
CN114213340A (zh) 2022-03-22
JP2024511069A (ja) 2024-03-12

Similar Documents

Publication Publication Date Title
WO2023159794A1 (zh) 2,4-二氨基嘧啶氧化物的制备方法
ES2323081T3 (es) Procedimiento para la produccion de 2-butanol mediante reduccion enzimatica de 2-butanona en un sistema de dos fases.
Czech et al. The [FeFe]-hydrogenase maturase HydF from Clostridium acetobutylicum contains a CO and CN− ligated iron cofactor
WO2021180019A1 (zh) 一种(s)-尼古丁的合成方法
Wang et al. NADP-specific electron-bifurcating [FeFe]-hydrogenase in a functional complex with formate dehydrogenase in Clostridium autoethanogenum grown on CO
US9371326B2 (en) Method for synthesizing sapropterin dihydrochloride
Savage et al. Carbon monoxide-dependent chemolithotrophic growth of Clostridium thermoautotrophicum
Ni et al. Highly stereoselective reduction of prochiral ketones by a bacterial reductase coupled with cofactor regeneration
CN101120094B (zh) 用于制备手性醇的方法
Hutten et al. Coenzyme M derivatives and their effects on methane formation from carbon dioxide and methanol by cell extracts of Methanosarcina barkeri
CN109706191B (zh) 一种托莫西汀中间体的酶催化合成方法
Kirimura et al. Production of p-aminosalicylic acid through enzymatic Kolbe–Schmitt reaction catalyzed by reversible salicylic acid decarboxylase
CN108264480B (zh) 阿维巴坦钠中间体的制备方法
Diender et al. Proteomic analysis of the hydrogen and carbon monoxide metabolism of Methanothermobacter marburgensis
CN107325113A (zh) 一种包含Salen单元的笼型共价有机框架化合物的制备方法
CN105274160B (zh) 一种酶法不对称还原制备(S)-N-boc-3-羟基哌啶的方法
Heiss et al. Asymmetric reduction of ethynyl ketones and ethynylketoesters by secondary alcohol dehydrogenase from Thermoanaerobacter ethanolicus
Fischer et al. N 5-Methyltetrahydromethanopterin: coenzyme M methyltransferase in methanogenic archaebacteria is a membrane protein
Herter et al. Laccase-mediated synthesis of 2-methoxy-3-methyl-5-(alkylamino)-and 3-methyl-2, 5-bis (alkylamino)-[1, 4]-benzoquinones
Nealon et al. I86A/C295A mutant secondary alcohol dehydrogenase from Thermoanaerobacter ethanolicus has broadened substrate specificity for aryl ketones
Li et al. One-pot four-enzyme synthesis of ketoses with fructose 1, 6-bisphosphate aldolases from Staphylococcus carnosus and rabbit muscle
Ishikawa et al. Microcalorimetric study of aerobic growth of Escherichia coli in batch culture
Romesser et al. CDR factor, a new coenzyme required for carbon dioxide reduction to methane by extracts of Methanobacterium thermoautotrophicum
CN102978249A (zh) 6-氰基-（3r,5r）-二羟基己酸叔丁酯的生物制备方法
CN101240299A (zh) 一种酵母细胞催化还原芳香酮制备光学活性醇的方法

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2023557685

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 18284455

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22928065

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2022928065

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2022928065

Country of ref document: EP

Effective date: 20231025